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Mitral Valve Surgery in High-Risk Patients?
A Meta-Analysis of Observational Studies
Marco Moscarelli, MD, Khalil Fattouch, MD, PhD, Roberto Casula, MD,
Giuseppe Speziale, MD, PhD, Patrizio Lancellotti, MD, PhD, and
Thanos Athanasiou, MD, PhD
National Heart and Lung Institute and Department of Surgery and Cancer, Imperial College London, London, United Kingdom; GVM
Care and Research, Villa Maria Eleonora, Palermo; GVM Care, Anthea Hospital, Bari, Italy; Department of Cardiology, University of
Liege Hospital, Liege, Belgium; and the GVM Care and Research GroupBackground. Minimally invasive valve surgery is
related to certain better postoperative outcomes. We
aimed to assess the role of minimally invasive mitral
valve surgery in high-risk patients.
Methods. A systematic literature review identiﬁed
eight studies of which seven fulﬁlled criteria for meta-
analysis. Outcomes for a total of 1,254 patients (731
were conventional standard sternotomy and 523 were
minimally invasive mitral valve surgery) were submitted
to meta-analysis using random effects modeling. Het-
erogeneity and subgroup analysis with quality scoring
were assessed. The primary end point was early mortal-
ity. Secondary end points were intraoperative and post-
operative outcomes and long-term follow-up.
Results. Minimally invasive mitral valve surgery
conferred comparable early mortality to standard ster-
notomy (p [ 0.19); it was also associated with a lower
number of units of blood transfused (weighted mean
difference, L1.93; 95% conﬁdence interval [CI], L3.04Accepted for publication Aug 7, 2015.
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and Cancer, Imperial College, Paddington, London, W2 1NY, United
Kingdom; email: m.moscarelli@imperial.ac.uk.
 2016 by The Society of Thoracic Surgeons
Published by Elsevierto L0.82; p [ 0.0006) and atrial ﬁbrillation rate (odds
ratio, 0.49; 95% CI, 0.32 to 0.74; p [ 0.0007); however,
cardiopulmonary bypass time was longer (weighted
mean difference, 20.88; 95% CI, L1.90 to 43.65; p [
0.07). There was no difference in terms of valve repair
rate (odds ratio, 1.51; 95% CI, 0.89 to 2.54; p [ 0.12), and
the incidence of stroke was signiﬁcantly lower in the
high-quality analysis with no heterogeneity (odds ratio,
0.35; 95% CI, 0.15 to 0.82; p [ 0.02; c2, 1.67; I2, 0%; p [
0.43).
Conclusions. Minimally invasive mitral valve surgery
is a safe and comparable alternative to standard sternot-
omy in patients at high risk, with similar early mortality
and repair rate and better postoperative outcomes,
although a longer cardiopulmonary bypass time is
required.
(Ann Thorac Surg 2016;101:981–9)
 2016 by The Society of Thoracic Surgeonss a result of the aging of the cardiac surgery popu-Alation, physicians have to deal with individuals of
accumulated comorbidity. Cardiac surgeons have been
mastering minimally invasive surgery techniques for
several years with favorable results [1], and these
beneﬁts may be particularly evident in patients at high
risk who, more than others, are prone to experience
adverse events postoperatively. However, minimally
invasive surgery may be associated with an increased
incidence of stroke and aortic dissection, as well as
signiﬁcantly longer cardiopulmonary bypass (CPB)
time [2], which can be classiﬁed as technical- or
learning curve–related drawbacks. So far, there are
virtually no prospective randomized trials comparing
minimally invasive valve surgery (MIMVS) and standardsternotomy (ST) in an unbiased way, and the majority
of evidence rely on observational studies. Moreover,
deﬁnition of the level of risk has been a controversial
issue, mainly because the currently available tools of
risk prediction in cardiac surgery such as EuroSCORE
II [3] and The Society of Thoracic Surgery Predicted of
Risk of Mortality [4] lose calibration and discrimination
in the upper boundaries or deciles of surgical risk.
Hence, deﬁning where to draw the “red line” above
which patients should be considered at high risk re-
mains a challenge and an issue of debate. The aims of
this study are to identify (1) whether minimally inva-
sive mitral valve surgery (MIMVS) may offer a mor-
tality advantage in patients at increased risk for
surgery when compared with the counterpart, ST; (2)
whether the repair rate is the same; (3) whether the
reduced rate of postoperative complications observed
in the general MIMVS population is maintained or
even improved in these subgroups; and ﬁnally (4)
whether there are any differences in terms of long-
term efﬁcacy.0003-4975/$36.00
http://dx.doi.org/10.1016/j.athoracsur.2015.08.050
Abbreviations and Acronyms
AF = atrial ﬁbrillation
CI = conﬁdence interval
CPB = cardiopulmonary bypass
MIMVS = minimally invasive mitral valve
surgery
OR = odds ratio
PRC = packed red cells
ST = sternotomy
WMD = weighted mean difference
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Literature Search
A literature search was performed using PubMed, Ovid,
Embase, Medline, and Cochrane databases using the
MeSH terms “minimally invasive mitral valve” and
“high-risk,” and we included in the MeSH terms all the
EuroSCORE II risk factors. In addition, our search was
extended to include the clinicaltrials.gov database andFig 1. Search strategy.“gray” literature for further rigor. The “related articles”
function in PubMed was also used to ensure complete-
ness. The last date for this search was February 1, 2015
(Fig 1).Inclusion and Exclusion Criteria
All articles reporting outcomes for MIMVS (experi-
mental group) and ST (control group) were included.
Studies were excluded from the review if (1) incon-
sistency of data did not allow valid extraction; (2) data
were duplicated; (3) the experimental or control group
was robotic mitral valve intervention; and (4) the trial
or study was carried out on animal models. Based on
these criteria, two assessors (M.M., K.F.) independently
selected studies for further examination by title and
abstract review. All potentially eligible studies were
retrieved in full for further evaluation. Any disagree-
ment was resolved by discussion with a third author
(T.A.). Statistical concordance testing was performed
using Cohen’s kappa coefﬁcient to measure interrate
agreement.
Table 1. Criteria for Quality Assessment
Quality Checklist
Selection
1. Assignment for treatment—any criteria reported? (If yes,
1 star)
2. How representative was the reference group (ST) in
comparison to the general population for mitral surgery?
(If yes, 1 star; no star if the patients were selected or selection
of group was not described)
3. How representative was the reference group (MIMVS) in
comparison to the general population for mitral surgery?
(If drawn from the same community as the reference group,
1 star; no star if drawn from a different source or selection of
group was not described)
Comparabilitya
4. Groups comparable for risk factors 1, 2, 3, 4, 5, 6, 7, 8, 9
(if yes, 1 star was assigned for each of these; no star was
assigned if the groups differed)
5. Groups comparable for risk factors 10, 11, 12, 13, 14, 15, 16, 17
(if yes, 1 star was assigned for each of these; no star was
assigned if the two groups differed)
Outcome assessment
6. Clearly deﬁned outcome of interest (if yes, 1 star)
7. Follow-up (1 star if described)
a Comparability includes all the EuroSCORE II risk factors. Comparability
variables were (1) age; (2) sex; (3) renal function; (4) extracardiac arterio-
pathy; (5) poor mobility; (6) previous cardiac surgery; (7) chronic lung
disease; (8) active endocarditis; (9) critical preoperative state; (10) insulin-
dependent diabetes mellitus; (11) New York Heart Association; (12) Ca-
nadian Cardiovascular Society class IV; (13) left ventricular function; (14)
recent myocardial infarction; (15) pulmonary hypertension; (16) urgency;
and (17) combined.
MIMVS ¼ minimally invasive mitral valve surgery; ST ¼ standard
sternotomy.
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CData Analysis
Two authors (M.M., K.F.) independently extracted the
following data from each paper using a predeﬁned pro-
tocol including ﬁrst author, year of publication, study
type, number of subjects, and study population de-
mographics. Speciﬁc outcome data, where possible, were
extracted for the following: (1) primary end points: early
mortality (including 30-day or in-hospital mortality), and
(2) secondary end points, including CPB time, mitral
repair rate, number of units of packed red cells (PRC)
transfused, reopening for bleeding, prolonged intubation
(deﬁned as more than 48 hours), atrial ﬁbrillation (AF),
acute renal failure, atrioventricular block requiring
pacemaker implantation, and length of stay. Meta-
analysis was performed in line with recommendations
from the Cochrane Collaboration and in accordance with
both PRISMA (Preferred Reporting Items for Systematic
Reviews and Meta-Analyses) and MOOSE (Meta-analysis
Of Observational Studies in Epidemiology) guidelines
[5, 6]. Analysis was conducted by use of Review Manager
version 5.1.7 for Windows (The Cochrane Collaboration,
Software Update, Oxford, UK) and STATA v.11 statistical
analysis software (StataCorp, College Station, TX). Data
were analyzed using a weighted DerSimonian–Laird
random effects model. Continuous data were investigated
using weighted mean difference (WMD) as the summary
statistic, reported with 95% conﬁdence intervals (CI). The
point estimate of the WMD was considered statistically
signiﬁcant at a probability value of less than 0.05, if the
95% CI did not include the value zero. Categorical vari-
ables were analyzed using the odds ratio (OR). An OR of
less than 1 favored the treatment group, and the point
estimate of the OR is considered statistically signiﬁcant
at the probability value of less than 0.05 level, if the 95%
CI does not include the value 1.Heterogeneity
Interstudy heterogeneity was explored using the c2 sta-
tistic, but the I2 value was calculated to quantify the de-
gree of heterogeneity across trials that could not be
attributable to chance alone. When I2 was more than 50%,
signiﬁcant statistical heterogeneity was considered to be
present. Three strategies were used to assess data validity
and heterogeneity: (1) subgroup analysis of higher-
quality studies (quality score > 7); (2) funnel plots to
evaluate publication bias; and (3) meta-regression to
assess the effect of covariates on the log OR for the pri-
mary outcome of interest.Quality Scoring
Quality assessment of each study was performed by
attributing a quality assessment score using a modiﬁca-
tion of the Newcastle–Ottawa scale [6] that included all 17
EuroSCORE II risk factors. Studies attaining greater than
the median score of 7 (from a maximum of 17) were
deﬁned as having “higher matching quality” and were
included in the subgroup analysis. Modiﬁed Newcastle–
Ottawa scoring criteria are shown in Table 1.Risk of Bias Analysis
A domain-based evaluation of risk of bias was performed
in accordance with the guidelines outlined in the
Cochrane Handbook for Systematic Reviews of In-
terventions Version 5.1.0 [7]. Two authors (M.M., K.F.)
subjectively reviewed all studies included in this review
and assigned a value of “yes,” “no,” or “unclear” to the
following questions: (1) Was the allocation sequence
adequately generated? (2) Was allocation adequately
concealed? (3) Was there blinding of participants,
personnel, and outcome assessors? (4) Were incomplete
outcome data sufﬁciently assessed? (5) Are reports in the
study free of the suggestion of selective outcome report-
ing? “Risk of bias” plots were performed using Review
Manager version 5.1.7 for Windows (The Cochrane
Collaboration, Software Update).Results
Our search revealed seven studies [8–14] fulﬁlling these
inclusion criteria, producing a pooled data set of 1,254
patients of whom 731 underwent ST and 523 underwent
MIMVS (Table 2). There was 100% concordance between
reviewers, equating to a Cohen’s kappa coefﬁcient of 1.
Five studies were retrospective observational in design
[8, 10, 12–14], and two were propensity-matched studies
Table 2. Study Characteristics
Author, Year (total patients),
Study Type
Inclusion
Criteria
Exclusion
Criteria
MI/ST
(n)
Mean Age (years)
Sex
(male)
Ejection
Fraction <
0.30 (n)
Infective
Endocarditis (n)
Serum Creatinine
(g/dL)
COPD
(n) Redo (n)
CCF
(NYHA
III/IV)
(n)
MI ST MI ST MI ST MI ST MI ST MI ST MI ST MI ST
Mihos et al 2014 (n ¼ 50),
retrospective observational
a A, C 22/28 65  12 62  16 17 18 NS NS 22a 28a 1.23  0.8 1.61  1.7 9 10 4 2 NS NS
Tang et al 2013 (n ¼ 180),
propensity-matched
a, b, c, d, A 90/90 60.02  1.38 60.42  1.43 NS NS NS NS 16 11 2.5  0.2a 2.5  0.2a 20 18 34 34 80 79
Iribarne et al 2012 (n ¼ 175),
retrospective observational
a A, B 70/105 78.6  3.3a 79.4  3.9a 43 70 NS NS 3 4 1.0  0.04 1.1  0.04 13 4 0 0 18 39
Holzhey et al 2011 (n ¼ 286),
propensity-matched
a, b, c, d A, D 143/143 76  3.9a 76  3.6a 7 7 7 7 6 8 NS NS 13 12 21 22 NS NS
Sharony et al 2006 (n ¼ 277),
retrospective observational
a, b A 100/177 NS 64.9  1.0 NS 30 NS 48 NS NS NS NS NS 56 100a 177a NS 275
Bolotin et al 2004 (n ¼ 71),
retrospective observational
a A 38/33 67.9  1.5 62.9  2.0 NS NS NS NS NS NS NS NS NS NS 38a 33a 24 20
Burfeind et al 2002 (n ¼ 215),
retrospective observational
a A, C 60/155 60  14 58  16 33 122 NS NS NS NS NS NS NS NS 60a 155a NS NS
a Indicates the main risk factor considered in the study.
Inclusions: a ¼ MI through right mini-thoracotomy with endo-clamp or direct clamping or ﬁbrillating heart; b ¼ tricuspid valve surgery; c ¼ atrial septal defect or patent foramen ovale; d ¼ atrial ﬁbrillation
ablation; e ¼ intention to treat analysis.
Exclusions: A ¼ standard contraindications: right-sided chest surgery, femoral vessel difﬁculties, minimally invasive mitral valve surgeons not available; B ¼ reoperation; C ¼ concomitant tricuspid; D ¼ very
low ejection fraction.
CCF ¼ congestive cardiac failure; COPD ¼ chronic obstructive pulmonary disease; MI ¼ minimally invasive; NS ¼ not speciﬁed for propensity analysis; NYHA ¼ New York Heart Asso-
ciation; ST ¼ sternotomy.
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C[9, 11]. Two studies, although observational, included two
very homogeneous populations [8, 10]. One study re-
ported an amalgamated secondary outcome for mini-
mally invasive mitral and aortic valve surgery; thus,
relevant data could not be retrieved [12]. Another study
reported amalgamated outcomes for both primary (mor-
tality) and secondary outcomes for minimally invasive
mitral and aortic valve surgery, so it was subsequently
excluded from our quantitative analysis to avoid any
contamination of the experimental group and reduce
clinical heterogeneity [15].
Deﬁnition of “High Risk”
As neither the EuroSCORE II nor The Society of Thoracic
Surgery Predicted of Risk of Mortality was reported for
each study, we deﬁned “high risk” as patients with
established risk factors who qualiﬁed to be included in
the EuroSCORE II. Mihos and colleagues [8] included
infective endocarditis and chronic obstructive pulmonary
disease (40.9%) and redo operations (18.1%); Tang and
associates [9] included patients with chronic renal failure
and New York Heart Association functional class IV
(43%), redo operations (37.7%), infective endocarditis
(17.7%), and chronic obstructive pulmonary disease
(22.2%); Iribarne and coworkers [10] included patients
older than 75 years and those with chronic obstructive
pulmonary disease (18.5%); Holzhey and colleagues [11]
included patients older than 70 years and those with redo
operations (14.7%), chronic obstructive pulmonary dis-
ease (8.6%), infective endocarditis (4.9%), and left ven-
tricular ejection fraction of less than 30% (4.9%); and
Sharony and associates [12], Bolotin and coworkers [13],
and Burfeind and colleagues [14] included speciﬁcally
redo patients (Table 2). Combined procedures (tricuspid
valve) were also included in the studies by Tang and
coworkers [9], Holzhey and colleagues [11], and Sharony
and associates [12]. Moreover, the modiﬁed Newcastle–
Ottawa scale based on 17 EuroSCORE II risk factors was
used to both check comparability and numbers of risk
factors included.
Primary Outcome
A summary of both primary and secondary end points is
shown in Table 3. We observed no difference in terms of
early mortality between MIMVS and ST (OR, 0.55; 95%
CI, 0.23 to 1.34; p ¼ 0.19); however, heterogeneity was
observed (c2, 15.90; p ¼ 0.01; I2, 62%; Fig 2A).
Secondary End Points
Minimally invasive mitral valve surgery was associated
with prolonged CPB time (WMD, 20.88; 95% CI, 1.90 to
43.65; p ¼ 0.07), but a similar mitral valve repair rate (OR,
1.51; 95% CI, 0.89 to 2.54; p ¼ 0.12); however, the number
of PRC units transfused per patient was signiﬁcantly
lower (WMD, 1.93; 95% CI, 3.04 to 0.82; p ¼ 0.0006) as
was the incidence of AF (OR, 0.49; 95% CI, 0.32 to 0.74; p ¼
0.0007). There was no signiﬁcant difference with regard to
all the other secondary outcomes considered; heteroge-
neity was found with regard to CPB time, mitral repair
Fig 2. Forest plots of minimally invasive mitral valve surgery (MIMVS) versus standard sternotomy (ST): (A) overall early mortality and (B) high-
quality studies. (CI ¼ conﬁdence interval.)
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Crate, number of PRC units transfused, and length of stay
(Table 3).
Quality Scoring and Sensitivity Analysis
HIGH-QUALITY STUDIES. By using a modiﬁed version of the
Newcastle–Ottawa scale, we assigned 1 point for each
EuroSCORE II risk factor included and comparable be-
tween the MIMVS and ST groups. The overall quality of
studies is outlined in Table 4. Of the seven studies
included in this review, four were considered to be of
high quality, scoring above the median of 7 points
(Table 4) [8–11]. Analysis of high-quality studies did not
demonstrate a signiﬁcant difference in terms of the pri-
mary outcome early mortality (OR, 0,98; 95% CI, 0.45 to
2.10; p ¼ 0.93), but most importantly, no heterogeneityTable 4. Quality Scoringa
Authors (no. of patients)
Selection
1 2 3
Mihos 2014 (n ¼ 50) . . .
Tang 2013 (n ¼ 180) . . .
Iribarne 2012 (n ¼ 175) . . .
Holzhey 2011 (n ¼ 286) . . .
Sharony 2006 (n ¼ 277) . . .
Bolotin 2004 (n ¼ 71) . . .
Burfeind 2002 (n ¼ 215) . . .
a Quality scoring system based on EuroSCORE II modiﬁed Newcastle–Otta
variables.was detected for this primary outcome (c2, 4.25; I2, 29%;
p ¼ 0.29; Table 5; Fig 2B.). It seems that study quality can
be a factor contributing to statistical heterogeneity among
studies. In terms of secondary outcomes, as per overall
analysis, the number of PRC units transfused per patient
was lower (WMD, 1.57; 95% CI, 3.04 to 0.10; p ¼ 0.04);
moreover, the incidence of stroke was statistically
signiﬁcantly lower (OR, 0.35; 95% CI, 0.15 to 0.82; p ¼ 0.02)
with no heterogeneity (c2, 1.67; I2, 0%; p ¼ 0.43). Also,
there was no difference with regard to mitral valve repair
rate (OR, 1.07; 95% CI, 0.68 to 1.69; p ¼ 0.760) with no
heterogeneity (c2, 5.76; I2, 48%; p ¼ 0.12); however, a
difference in CPB time was observed (WMD, 33.45; 95%
CI, 19.58 to 86.48; p ¼ 0.04), but heterogeneity was found
(p < 0.00001; Table 5).Comparability Outcome
Total4 5 6 7
****** *** * * 11
******** *** * * 13
**** ** * * 8
******* *** * * 12
. . * . 1
. * * . 2
* . * . 2
wa scale. Asterisks indicate points scored for risk factor comparability
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CHETEROGENEITY ASSESSMENT: BIAS EXPLORATION. In accordance
with Cochrane guidelines [7], risk of bias analysis was
performed for all studies included in this review (Fig 3A).
Overall, a high level of bias was detected attributable to
the nonrandomized, unblinded nature of the majority of
studies. In addition, to established bias assessment a
score was given for each of the following: (1) multicenter
trial, (2) propensity-matched study, and (3) confounder
adjustment. No study fulﬁlled all three of these criteria
(Fig 3A). Two studies were propensity matched [9, 11],
and two others were corrected for potential confounders
[8, 10]. Funnel plots were used to assess for publication
bias for all primary and secondary outcomes. Minor
funnel plot asymmetry was identiﬁed for primary
outcome (Fig 3B); no funnel plot asymmetry was observed
for the secondary outcomes stroke, PRC transfused per
patients, postoperative AF, prolonged ventilation time,
and reopening for bleeding.
Meta-Regression for Primary Outcome
Meta-regression analysis was performed for early mor-
tality. Variables assessed were EuroSCORE preoperative
risk factors and postoperative complications. Signiﬁcant
beneﬁcial association for MIMVS in relation to early
mortality was found between the log OR and redo oper-
ation (p ¼ 0.039; b, 0.77), postoperative AF (p ¼ 0.013;
b, 0.85), reopening for bleeding (p ¼ 0.009; b, 0.88), and
postoperative renal failure (p ¼ 0.008; b, 0.88).Comment
This study is the ﬁrst meta-analysis to date comparing
patients with comorbidities undergoing either MIMVS
or ST. Although minimally invasive technique is
associated with a steep learning curve, several favor-
able results have been reported in the context of pa-
tients who are at increased risk for surgery [16–18].
However, a precise deﬁnition of the level of risk is
somewhat difﬁcult to achieve, as it depends on multi-
ple factors, not only patients’ features. We identiﬁed
patients with comorbidities that are traditionally asso-
ciated with an increased morbidity and mortality after
surgery and deﬁned this subset of patients as “high
risk” for the purpose of our analysis. We demonstrated
that MIMVS is at least as safe as the standard
approach in terms of early mortality. Our ﬁndings are
in line with the International Society of Minimally
Invasive Surgery 2010 recommendation [2]. However,
we did not observe any difference in terms of stroke;
in fact in the high-quality studies subgroup analysis,
the incidence was even lower in the MIMVS group
with no heterogeneity.
High-quality studies analysis included series in which
redo patients, although represented, were not predomi-
nant. Thus, central cannulation was mainly used in the
studies by Iribarne and colleagues [10] and Tang and
coworkers [9], and either femoral or central cannulation
was used in the study by Mihos and associates [8],
whereas all patients were operated on using femoral
cannulation in the study by Holzhey and associates [11].
Fig 3. (A) Risk of bias assessment. (B) Funnel plot overall early mortality. (RR ¼ risk ratio; SE ¼ standard error.)
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CMoreover, a transthoracic aortic clamp was preferred
over an intraaortic balloon clamp in all four series.
In studies that included mainly redo operation patients
[12–14], both ventricular ﬁbrillation arrest and endo-
clamping were used, although direct clamping was
reported in some cases in one series [12].
As in other reports [1, 19], CPB time was signiﬁcantly
longer in the MIMVS group, but heterogeneity was
evident as expected for continuous parameters. Overall
meta-analysis also showed a reduced rate of post-
operative AF with no heterogeneity. We also did not
observe any differences in terms of achieving mitral valve
repair between the two groups.
Four studies [8–11] reported follow-up, with two
providing long-term follow-up [9, 11] (>5 years), but only
Tang and colleagues [9] observed signiﬁcantly longer
survival rate for the MIMVS group.
This meta-analysis study allowed inclusion of 1,254
patients who would be difﬁcult to accumulate prospec-
tively for this particular topic. This study has, however,
several limitations. Among the seven studies included,
none were randomized controlled trials. Although
MIMVS is associated with a signiﬁcant learning curve
and volume–outcome relationship, it was not possible to
quantify the impact of this on the outcomes reported in
this study; however, most of the cohorts included in the
meta-analysis have published on a similar topic before
and that could be interpreted as a high-volume experi-
ence. Nevertheless, bias in favor of the ST technique
cannot be ruled out. To minimize the baseline hetero-
geneity of the population included in this meta-analysis
because a EuroSCORE mean was not possible to calcu-
late, we used a modiﬁcation of the Ottawa–Newcastle
scale based on comparability of all EuroSCORE II risk
factors (Table 1). Another limitation of this study is that
this meta-analysis included relatively limited mitral-
speciﬁc long-term outcomes. In terms of follow-up, four
studies reported data; of these, two included long-term
survival [9, 11]. Only survival was reported, with no
mention of freedom from reintervention—either
catheter-based procedures or redo operation—or New
York Heart Association functional class; hence, the long-term impact of MIMVS on high-risk patients in terms of
durability of repair or freedom from reintervention on
the mitral valve as well as functional class could not be
assessed. Further studies are required to investigate the
potential subgroup of patients in whom MIMVS may be
of greater beneﬁt.References
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systematic review. Innovations (Phila) 2011;6:84–103.STATISTICAL COMMENTARYMoscarelli and colleagues [1] provide a systematic review
and meta-analysis of observational studies of minimally
invasive mitral valve surgical procedures in high-risk
patients. By combining results across seven studies
meeting the inclusion criteria, they show comparable
early mortality between minimally invasive mitral valve
procedures and standard sternotomy. In addition, they
report similar repair rates and better postoperative out-
comes despite longer cardiopulmonary bypass times.
This report is noteworthy for several reasons. First, it
reﬂects the high standards of conduct and reporting of
systematic reviews and meta-analyses required by the
Preferred Reporting Items for Systematic Reviews and
Meta-Analysis (PRISMA). The implementation of stan-
dards adds to the reproducibility of studies such as this.
Second, the authors clearly report their literature search
strategy, which included searching multiple databases;
their approach to data extraction (two readers); and the
classiﬁcation used for assessing the quality of the original
studies and threats to bias. Third, they follow standard
approaches todata analysis in the settingof ameta-analysis
to assess variations in results among the original studies
(heterogeneity), and they thenuse plots to demonstrate the
distribution of results. These methods and reporting
standards should now be consistently implemented across
meta-analyses of randomized trials and observational
studies.
Beyond reporting, why pay attention to this article?
Importantly, this report demonstrates the potential for
systematic review and meta-analysis to add power to
address questions for which the original individual studies
did not provide sufﬁcient evidence. This is particularly
helpful for side effects, adverse events, and measures that
go beyond the original efﬁcacy or effectiveness of in-
terventions. Efﬁcacy and effectiveness studies are typically
powered to estimate the magnitude of the main effect
(beneﬁt) and are not powered to quantify themagnitude of
even important adverse events (possible harms). The
seven studies included in this analysis ranged from 22
patients undergoing minimally invasive procedures and
28 undergoing sternotomy, up to 143 in the minimally
invasive procedures group and 143 in the comparisonsternotomy group. The combined analysis, which
weighted the studies according to the original precision of
estimates, provides a summary across all 1,254 patients
(523 minimally invasive mitral valve procedures and 731
standard sternotomy).
In addition to summarizing the published evidence, a
systematic review and meta-analysis ideally can identify
gaps in the literature, or implications for future studies
to address uncertainties remaining after the systematic
review. Here the authors note that subgroups of patients
for whom minimally invasive procedures may be of
greater beneﬁt cannot be identiﬁed at present. Better and
more consistent reporting of comorbidity, and the strat-
iﬁcation of original studies on levels of risk, may help
address this gap. Alternatively, by use of the data in the
existing studies, an individual patient data meta-analysis
with a central data center could implement analysis with
the use of common deﬁnitions across the studies in a
combined repeated analysis. This approach can use a
multilevel analysis that controls for the original study
design while also analyzing individual level data. This
approach further reduces variation among studies
introduced by the use of differing cutpoints and ap-
proaches to analysis. Consistent deﬁnitions of risk strata
may be more easily implemented in such an analysis.
Additional data will help reﬁne approaches to assessing
the tradeoff of surgical approaches for high-risk patients
with comorbidities.
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